Silver Book Fact

Savings associated with t-PA treatment for ischemic stroke patients

A $600 net savings is associated with each ischemic stroke patient treated with t-PA. In 2005, only 2% of all ischemic stroke patients received t-PA. If that percentage was increased to 4% the realized cost savings would be approximately $15 million. If increased to 20%, the savings would be around $74 million.

Demaerschalk B, Yip T. Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States. Stroke. 2005; 36(11): 2500-3. http://stroke.ahajournals.org/cgi/content/full/36/11/2500

Reference

Title
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Publication
Stroke
Publication Date
2005
Authors
Demaerschalk B, Yip T
Volume & Issue
Volume 36, Issue 11
Pages
2500-3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Use of antihypertensive therapies avoided an estimated $10.7 billion in 2002 direct medical costs as a result of fewer strokes. They also avoided an estimated $5.8 billion in 2002…  
  • There are 23 medicines in development for stroke, the third leading cause of death after heart disease and cancer.  
  • Ischemic stroke patients treated with t-PA (a drug used to treat blood clots) within 3 hours of onset are 33% more likely to be free of disability 3 months after…  
  • A recent data analysis of more than 2,700 stroke patients from the U.S. and Europe confirmed tPA’s effectiveness, which could save the U.S. nearly $50 million a year.  
  • A study exploring the decline in deaths attributable to cardiovascular disease in the U.S. from 1980 to 2000 suggested that approximately 47% of the decrease was due to the increased…